Search research articles
Contact Us
Filters
Showing results (101-110 of 387) with videos related to
Page
of 39
Sort By:
The Oncologist
|
April 23, 2020
Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma
Frédérique St-Pierre, Stephen M Broski, Betsy R LaPlant, et al.
Blood Cancer Journal
|
November 14, 2018
Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma
Jing Jing Han, Megan O'byrne, Mary J Stenson, et al.
British Journal of Haematology
|
June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
Myron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Clinical Lymphoma & Myeloma
|
November 21, 2007
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Gregory A Wiseman, Peter S Conti, Katie Vo, et al.
Blood Cancer Journal
|
March 14, 2018
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
Rebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, et al.
Leukemia Research
|
August 2, 2006
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression
Michael Kline, Kathleen Donovan, Linda Wellik, et al.
American Journal of Hematology
|
December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin
Vijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
Blood Advances
|
February 26, 2021
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma
Catherine S Diefenbach, Brandilyn A Peters, Huilin Li, et al.
Leukemia & Lymphoma
|
March 15, 2017
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue
Anthony Q Pham, Stephen M Broski, Thomas M Habermann, et al.
Clinical Lymphoma
|
January 8, 2005
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
Stephen M Ansell, Russell J Schilder, Peter C Pieslor, et al.
Page
of 39
Search research articles
Search
Showing results (101-110 of 387) with videos related to
Sort By:
Page
of 39
The Oncologist
|
April 23, 2020
Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma
Frédérique St-Pierre, Stephen M Broski, Betsy R LaPlant, et al.
Blood Cancer Journal
|
November 14, 2018
Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma
Jing Jing Han, Megan O'byrne, Mary J Stenson, et al.
British Journal of Haematology
|
June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
Myron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Clinical Lymphoma & Myeloma
|
November 21, 2007
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Gregory A Wiseman, Peter S Conti, Katie Vo, et al.
Blood Cancer Journal
|
March 14, 2018
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
Rebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, et al.
Leukemia Research
|
August 2, 2006
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression
Michael Kline, Kathleen Donovan, Linda Wellik, et al.
American Journal of Hematology
|
December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin
Vijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
Blood Advances
|
February 26, 2021
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma
Catherine S Diefenbach, Brandilyn A Peters, Huilin Li, et al.
Leukemia & Lymphoma
|
March 15, 2017
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue
Anthony Q Pham, Stephen M Broski, Thomas M Habermann, et al.
Clinical Lymphoma
|
January 8, 2005
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
Stephen M Ansell, Russell J Schilder, Peter C Pieslor, et al.
Page
of 39